{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:53:24Z","timestamp":1792166004453,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s13045-014-0088-y","type":"journal-article","created":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T18:11:23Z","timestamp":1417716683000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors"],"prefix":"10.1186","volume":"7","author":[{"given":"Zhong","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Janin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,5]]},"reference":[{"key":"88_CR1","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES: The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011, 117: 5019-5032. 10.1182\/blood-2011-01-293050.","journal-title":"Blood"},{"key":"88_CR2","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D: International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008, 26: 4124-4130. 10.1200\/JCO.2008.16.4558.","journal-title":"J Clin Oncol"},{"key":"88_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0092-8674(02)00625-6","volume":"108","author":"RW Johnstone","year":"2002","unstructured":"Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002, 108: 153-164. 10.1016\/S0092-8674(02)00625-6.","journal-title":"Cell"},{"key":"88_CR4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1182\/blood-2004-07-2761","volume":"106","author":"JC Reed","year":"2005","unstructured":"Reed JC, Pellecchia M: Apoptosis-based therapies for hematologic malignancies. Blood. 2005, 106: 408-418. 10.1182\/blood-2004-07-2761.","journal-title":"Blood"},{"key":"88_CR5","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/nri953","volume":"2","author":"AL Shaffer","year":"2002","unstructured":"Shaffer AL, Rosenwald A, Staudt LM: Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002, 2: 920-932. 10.1038\/nri953.","journal-title":"Nat Rev Immunol"},{"key":"88_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1517\/14728222.2013.736499","volume":"17","author":"S Fulda","year":"2013","unstructured":"Fulda S: Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer. Expert Opin Ther Targets. 2013, 17: 195-201. 10.1517\/14728222.2013.736499.","journal-title":"Expert Opin Ther Targets"},{"key":"88_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1365-2141.2005.05898.x","volume":"132","author":"G Valente","year":"2006","unstructured":"Valente G, Manfroi F, Peracchio C, Nicotra G, Castino R, Nicosia G, Kerim S, Isidoro C: cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy. Br J Haematol. 2006, 132: 560-570. 10.1111\/j.1365-2141.2005.05898.x.","journal-title":"Br J Haematol"},{"key":"88_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35106079","volume":"1","author":"P Marks","year":"2001","unstructured":"Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001, 1: 194-202. 10.1038\/35106079.","journal-title":"Nat Rev Cancer"},{"key":"88_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1756-8722-6-69","volume":"6","author":"P Reimer","year":"2013","unstructured":"Reimer P, Chawla S: Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma. J Hematol Oncol. 2013, 6: 69-10.1186\/1756-8722-6-69.","journal-title":"J Hematol Oncol"},{"key":"88_CR10","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1038\/jid.2012.125","volume":"132","author":"N Al-Yacoub","year":"2012","unstructured":"Al-Yacoub N, Fecker LF, Mobs M, Plotz M, Braun FK, Sterry W, Eberle J: Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling. J Investig Dermatol. 2012, 132: 2263-2274. 10.1038\/jid.2012.125.","journal-title":"J Investig Dermatol"},{"key":"88_CR11","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1158\/1078-0432.CCR-12-3151","volume":"19","author":"L Odqvist","year":"2013","unstructured":"Odqvist L, Sanchez-Beato M, Montes-Moreno S, Martin-Sanchez E, Pajares R, Sanchez-Verde L, Ortiz-Romero PL, Rodriguez J, Rodriguez-Pinilla SM, Iniesta-Martinez F, Solera-Arroyo JC, Ramos-Asensio R, Flores T, Palanca JM, Bragado FG, Franjo PD, Piris MA: NIK controls classical and alternative NF-kappaB activation and is necessary for the survival of human T-cell lymphoma cells. Clin Cancer Res. 2013, 19: 2319-2330. 10.1158\/1078-0432.CCR-12-3151.","journal-title":"Clin Cancer Res"},{"key":"88_CR12","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1172\/JCI61205","volume":"122","author":"SA Pileri","year":"2012","unstructured":"Pileri SA, Piccaluga PP: New molecular insights into peripheral T cell lymphomas. J Clin Investig. 2012, 122: 3448-3455. 10.1172\/JCI61205.","journal-title":"J Clin Investig"},{"key":"88_CR13","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/leu.2009.41","volume":"23","author":"QL Zhang","year":"2009","unstructured":"Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, Zhao WL: The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia\/lymphoma cells apoptosis. Leukemia. 2009, 23: 1507-1514. 10.1038\/leu.2009.41.","journal-title":"Leukemia"},{"key":"88_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/40657","volume":"388","author":"M Irmler","year":"1997","unstructured":"Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J: Inhibition of death receptor signals by cellular FLIP. Nature. 1997, 388: 190-195. 10.1038\/40657.","journal-title":"Nature"},{"key":"88_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bjh.12108","volume":"160","author":"D McLornan","year":"2013","unstructured":"McLornan D, Hay J, McLaughlin K, Holohan C, Burnett AK, Hills RK, Johnston PG, Mills KI, McMullin MF, Longley DB, Gilkes A: Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. Br J Haematol. 2013, 160: 188-198. 10.1111\/bjh.12108.","journal-title":"Br J Haematol"},{"key":"88_CR16","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1182\/blood-2010-07-294470","volume":"117","author":"I Paz-Priel","year":"2011","unstructured":"Paz-Priel I, Houng S, Dooher J, Friedman AD: C\/EBPalpha and C\/EBPalpha oncoproteins regulate nfkb1 and displace histone deacetylases from NF-kappaB p50 homodimers to induce NF-kappaB target genes. Blood. 2011, 117: 4085-4094. 10.1182\/blood-2010-07-294470.","journal-title":"Blood"},{"key":"88_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144: 646-674. 10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"88_CR18","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.4049\/jimmunol.181.8.5368","volume":"181","author":"N Zhang","year":"2008","unstructured":"Zhang N, Hopkins K, He YW: c-FLIP protects mature T lymphocytes from TCR-mediated killing. J Immunol. 2008, 181: 5368-5373. 10.4049\/jimmunol.181.8.5368.","journal-title":"J Immunol"},{"key":"88_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10495-011-0673-2","volume":"17","author":"R Martin-Perez","year":"2012","unstructured":"Martin-Perez R, Niwa M, Lopez-Rivas A: ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis. 2012, 17: 349-363. 10.1007\/s10495-011-0673-2.","journal-title":"Apoptosis"},{"key":"88_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00428-005-1264-9","volume":"446","author":"X Dolcet","year":"2005","unstructured":"Dolcet X, Llobet D, Pallares J, Matias-Guiu X: NF-kB in development and progression of human cancer. Virchows Arch. 2005, 446: 475-482. 10.1007\/s00428-005-1264-9.","journal-title":"Virchows Arch"},{"key":"88_CR21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1349-7006.2011.01904.x","volume":"102","author":"R Furumai","year":"2011","unstructured":"Furumai R, Ito A, Ogawa K, Maeda S, Saito A, Nishino N, Horinouchi S, Yoshida M: Histone deacetylase inhibitors block nuclear factor-kappaB-dependent transcription by interfering with RNA polymerase II recruitment. Cancer Sci. 2011, 102: 1081-1087. 10.1111\/j.1349-7006.2011.01904.x.","journal-title":"Cancer Sci"},{"key":"88_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.intimp.2013.06.027","volume":"17","author":"HM Zhong","year":"2013","unstructured":"Zhong HM, Ding QH, Chen WP, Luo RB: Vorinostat, a HDAC inhibitor, showed anti-osteoarthritic activities through inhibition of iNOS and MMP expression, p38 and ERK phosphorylation and blocking NF-kappaB nuclear translocation. Int Immunopharmacol. 2013, 17: 329-335. 10.1016\/j.intimp.2013.06.027.","journal-title":"Int Immunopharmacol"},{"key":"88_CR23","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","volume":"48","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, Yang WI, Kim HK, Min SK, Lee SS, Do IG, Suh C, Kim WS: Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer. 2012, 48: 3223-3231. 10.1016\/j.ejca.2012.06.003.","journal-title":"Eur J Cancer"},{"key":"88_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10549-012-2332-x","volume":"137","author":"M Kubo","year":"2013","unstructured":"Kubo M, Kanaya N, Petrossian K, Ye J, Warden C, Liu Z, Nishimura R, Osako T, Okido M, Shimada K, Takahashi M, Chu P, Yuan YC, Chen S: Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Res Treat. 2013, 137: 93-107. 10.1007\/s10549-012-2332-x.","journal-title":"Breast Cancer Res Treat"},{"key":"88_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/1471-2407-9-395","volume":"9","author":"A Lehmann","year":"2009","unstructured":"Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, Noske A, Muller BM, Bahra M, Neuhaus P, Dietel M, Kristiansen G, Weichert W: High class I HDAC activity and expression are associated with RelA\/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer. 2009, 9: 395-10.1186\/1471-2407-9-395.","journal-title":"BMC Cancer"},{"key":"88_CR26","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-2559.2009.03290.x","volume":"54","author":"L Marquard","year":"2009","unstructured":"Marquard L, Poulsen CB, Gjerdrum LM, de Nully BP, Christensen IJ, Jensen PB, Sehested M, Johansen P, Ralfkiaer E: Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology. 2009, 54: 688-698. 10.1111\/j.1365-2559.2009.03290.x.","journal-title":"Histopathology"},{"key":"88_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","volume":"277","author":"O Witt","year":"2009","unstructured":"Witt O, Deubzer HE, Milde T, Oehme I: HDAC family: what are the cancer relevant targets?. Cancer Lett. 2009, 277: 8-21. 10.1016\/j.canlet.2008.08.016.","journal-title":"Cancer Lett"},{"key":"88_CR28","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/jcb.22185","volume":"107","author":"PA Marks","year":"2009","unstructured":"Marks PA, Xu WS: Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem. 2009, 107: 600-608. 10.1002\/jcb.22185.","journal-title":"J Cell Biochem"},{"key":"88_CR29","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1038\/onc.2011.614","volume":"31","author":"A Bangert","year":"2012","unstructured":"Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, Hacker S, Vellanki SH, Lausen J, Debatin KM, Fulda S: Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene. 2012, 31: 4677-4688. 10.1038\/onc.2011.614.","journal-title":"Oncogene"},{"key":"88_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-7-11","volume":"7","author":"B Coiffier","year":"2014","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S: Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014, 7: 11-10.1186\/1756-8722-7-11.","journal-title":"J Hematol Oncol"},{"key":"88_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1756-8722-5-24","volume":"5","author":"S Jain","year":"2012","unstructured":"Jain S, Zain J, O\u2019Connor O: Novel therapeutic agents for cutaneous T-cell lymphoma. J Hematol Oncol. 2012, 5: 24-10.1186\/1756-8722-5-24.","journal-title":"J Hematol Oncol"},{"key":"88_CR32","doi-asserted-by":"crossref","unstructured":"Jaffe ES: The 2008 WHO classification of lymphomas: implications for clinical practice and translational research.Hematology Am Soc Hematol Educ Program 2009, 523\u2013531.,","DOI":"10.1182\/asheducation.V2009.1.523.0010523"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-014-0088-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-014-0088-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-014-0088-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-014-0088-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T06:50:19Z","timestamp":1630565419000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-014-0088-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["88"],"URL":"https:\/\/doi.org\/10.1186\/s13045-014-0088-y","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"26 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"88"}}